File No. SND/CT/21/000036
Government of India
Directorate General of Health Services
Central Drugs Standard Control Organisation
(Subsequent New Drugs Division)

FDA Bhawan, Kotla Road,
New Delhi-110002
Dated:

18 OCT 2021

To

M/s. Shilpa Medicare Limited.,
12-6-214/A1, Hyderabad Road, Raichur,
Karnataka (India) - 584135.

Subject: **Permission to conduct Phase II Clinical trial of Ursodiol Injection 625mg/25 ml (25mg/ml) - A Randomized, Single Blind, Placebo Controlled, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of Ursodiol Injection 625mg/25ml (25mg/ml) in Adults with moderate COVID 19 patients at a dose of 1750 mg/day via intravenous infusion. (Protocol No. URSO/SML/P2/2021, Version No. 2.0, Dated 14 Sep 2021) - Reg.**

CT NOC No.: CT/SND/172/2021

Sir,

With reference to your Application No. SND/CT04/FF/2021/25958 dated 24-05-2021 please find enclosed herewith the permission in Form CT-06, CT NOC No. **CT/SND/172/2021** to conduct the subject mentioned clinical trial under the provisions of New Drugs and Clinical Trial Rules, 2019.

This permission is subject to the conditions, as mentioned below.

Yours faithfully,

V.G.

(Dr. V. G. Somani)
Central Licensing Authority

Conditions of Permission

(i) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licencing Authority under rule 8;

(ii) Where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7:

Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:

Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;

(iii) In case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;

(iv) The Central Licencing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;

(v) Clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;

(vi) Clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;

(vii) Status of enrolment of the trial subjects shall be submitted to the Central Licencing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;

(viii) Six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licencing Authority electronically in the SUGAM portal;

(ix) In case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licencing Authority within thirty working days of such termination;

(x) Any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licencing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI of the New Drugs and Clinical Trials Rules, 2019;

(xi) In case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with the Chapter VI of the said Rules and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of the receipt of order issued by Central Licencing Authority in accordance with the provisions of the said Chapter;

(xii) In case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with the

Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of receipt of the order issued by the Central Licencing Authority in accordance with the provisions of the said Chapter;

(xiii) The premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licencing Authority who may be accompanied by officers of the State Licencing Authority or outside experts as authorised by the Central Licencing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;

(xiv) Where the New Drug or Investigational New Drug is found to be useful in clinical development, the sponsor shall submit an application to the Central Licencing Authority for permission to import or manufacture for sale or for distribution of new drug in India, in accordance with Chapter X of these rules, unless otherwise justified;

(xv) The Laboratory owned by any person or a company or any other legal entity and utilised by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licensing Authority and may be used for test or analysis of any drug for and on behalf of Central Licensing Authority;

(xvi) The Central Licencing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;

(xvii) The sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.

(xviii) Informed Consent Documents (ICD) viz. Patient Information Sheet (PIS) and Informed Consent Form (ICF) complete in all respect & must be got approved from the respective Ethics committee and submitted to CDSCO before enrolling first subject at the respective site.

(xix) It may kindly be noted that merely granting permission to conduct Clinical trial with the drug does not convey or imply that based on the Clinical trial data generated with the drug, permission to market this drug in the country will automatically be granted to you.

FORM CT-06

(See rules 22, 25, 26, 29 and 30)

PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG ~~OR INVESTIGATIONAL NEW DRUG~~

CT NOC NO.: CT/SND/172/2021

The Central Licensing Authority hereby permits **M/s Shilpa Medicare Ltd., 12-6-214/A1, Hyderabad Road, Raichur, Karnataka (India) – 584135** to conduct clinical trial of the new drug ~~or investigational new drug~~ as per **Protocol No. URSO/SML/P2/2021, Version No. 2.0, Dated 14 Sep 2021** in the below mentioned clinical trial sites.

2. Details of new drug or ~~investigational new drug~~:

Names of the new drug:	Ursodiol Injection 625 mg/25ml (25mg/ml)
Therapeutic class:	Anti-inflammatory
Dosage form:	Injection
Composition:	Each ml contains 25mg of Ursodiol
Indications:	Ursodeoxycholic acid (UDCA) injection 25mg/ml is proposed for as add-on therapy for covid-19 patients to control and inhibition of cytokine storm (CS) along with standard care treatment (ICMR & WHO).

Details of clinical trial sites

Sr. No.	Name of Principal Investigator & Trial sites	Ethics Committee Name/ Registration Number
1	Dr Jyotiranjan Sahoo, IMS & SUM Hospital, Bhubaneswar,	IEC IMS and SUM Hospital, IMS and SUM Hospital, K8 Kalinganagar Shampur Bhubaneswar Khordha, Orissa, India - 751003 ECR/627/Inst/OR/2014/RR-20
2	Dr Vinayak Sawardekar St. George's Hospital, Mumbai.	Institutional Ethics, Committee, GGMC, Mumbai. ECR/382/Inst/MH/2013/RR-19
3	Dr Anand Kumar, GSVM Medical College, Kanpur.	Ethics Committee GSVM Medical College, ECR/680/Inst/UP/2014/RR-20
4	Dr Reema Kashiva, Noble Hospital, Pune.	Noble Hospital Institutional Ethics committee ECR/259/Inst/MH/2013/RR-19
5	Dr Archana Gautam, KIMS, Karad.	Institutional Ethics Committee of Krishna Institute of Medical sciences, ECR/307/Inst/MH/2013/RR-20

6	Dr Sonali Nirhali, Life Point Hospital, Pune.	Lifepoint Research- Ethics Committee Life Point Multispecialty Hospital Pvt. Ltd ECR/751/Inst/MH/2015/RR-21

3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

(Dr. V. G. Somani)
Central Licensing Authority
Stamp

Dr. V. G. SOMANI
Drugs Controller General (India)
Dte. General of Health Services
Ministry of Health and Family Welfare
FDA Bhawan, Kotla Road, I.T.O.
New Delhi-110002

New Delhi
Date: 18 OCT 2021